Pharmaceuticals, Biotechnology & Life Sciences

Explore how pharma & biotech firms use RWE, value‑based contracts, and strategic M&A to beat patent cliffs, boost reimbursement speed, and grow revenue.

How Eli Lilly’s surge is lifting the biotech index toward record highs, proving high‑growth stocks can steer the sector when tech falters.

First‑9‑month review: Kangmei Pharma cuts revenue 11% yet slashes costs, boosts margins, and earns 600% higher profit thanks to asset sales, debt settlements, and disciplined cost control – but cash flow dips 30%. Click to see how it balances short‑…

Vertex Pharmaceuticals reports steady growth and new breakthrough therapies—CRISPR, CAR‑T, and CF drugs—hinting at future investor gains.

After a legal victory, Bayer AG’s share price rises—now investors await Q3 earnings for a clearer picture of risk‑adjusted growth and market sentiment.

Explore Eli Lilly’s 10% revenue surge driven by diabetes & obesity drugs, strong margins, and a $200 M DTx upside—why analysts boost its outlook.

Regeneron’s stock jumps 13% as 3Q revenue hits $5B and a new Sanofi immunology partnership expands, standing out amid a Nasdaq sell‑off.

Discover why AstraZeneca’s Q2 earnings beat the market, the drivers behind its oncology and rare‑disease growth, and the risks and opportunities shaping its future.

After a U.S. court win, Bayer AG’s shares climb as investors see the legal threat lifted, while tech sell‑offs and pharma earnings keep the Stoxx 600 volatile.

Discover how AstraZeneca’s oncology surge and late‑stage pipeline are driving growth, outpacing tech and banking volatility.